# Formulary Analysis: 2025 â†’ 2026 Comparison

## Executive Summaries

### Express Scripts

**Critical Changes Requiring Immediate Attention:**

- **STELARA Exclusion (Effective July 1, 2026):** The blockbuster ustekinumab product will be excluded mid-year, with patients transitioned to biosimilars IMULDOSA, SELARSDI, or YESINTEK. This affects patients with psoriasis, psoriatic arthritis, and Crohn's disease.
- **Movement Disorder Therapy Switch:** AUSTEDO and AUSTEDO XR are now excluded; INGREZZA becomes the preferred agent for tardive dyskinesia and Huntington's chorea.
- **Complement Inhibitor Exclusions:** SOLIRIS and ULTOMIRIS are excluded, with EPYSQLI and ENSPRYNG as alternatives.

**Major Biosimilar Preference Shifts:**
- Infliximab: INFLECTRA excluded; AVSOLA and generic infliximab now preferred
- Trastuzumab: KANJINTI and TRAZIMERA excluded; HERCESSI and OGIVRI now preferred
- Tocilizumab: ACTEMRA excluded; AVTOZMA IV and TYENNE preferred
- Adalimumab: HUMIRA and CYLTEZO excluded; preferred biosimilars consolidated

**Notable Additions:** SPRAVATO (esketamine), INVEGA long-acting antipsychotics, INGREZZA/INGREZZA SPRINKLE, TYRUKO (natalizumab biosimilar)

ðŸ“„ **Detailed Analysis:** [pdf_direct.md](express_scripts/pdf_direct.md) | [txt_extraction.md](express_scripts/txt_extraction.md)

---

### OptumRx

**Structural Change:** The formulary consolidates from 5 tiers to 3 tiers, eliminating dedicated specialty tiers.

**Critical Exclusions Requiring Member Action:**
- **Diabetes Devices:** All FreeStyle Libre CGM products excluded; members must transition to Dexcom G6/G7
- **Insulins:** Levemir and Tresiba removed; members should switch to Lantus, Basaglar, or Toujeo
- **Migraine:** Ajovy (fremanezumab) excluded; alternatives include Aimovig, Emgality, or Nurtec
- **Multiple Sclerosis:** Copaxone 40mg brand excluded, plus Ocrevus and Tysabri excluded

**Major Additions:**
- **Weight Management:** Wegovy and Zepbound added at Tier 2 with prior authorization
- **Pain Management:** Journavx added as a novel non-opioid analgesic
- **Mental Health:** Zurzuvae added as first oral treatment for postpartum depression
- **Alzheimer's:** LEQEMBI and KISUNLA (anti-amyloid therapies) now covered

**Cost-Saving Generic Additions:** pregabalin (Lyrica), lenalidomide (Revlimid), nebivolol (Bystolic), desvenlafaxine ER (Pristiq)

ðŸ“„ **Detailed Analysis:** [pdf_direct.md](optumrx/pdf_direct.md) | [txt_extraction.md](optumrx/txt_extraction.md)

---

### UnitedHealthcare

**Most Impactful Changes:**

- **Major Cost Savings:** Generic rivaroxaban (Xarelto) added at Tier 2, offering significant savings for anticoagulant users
- **Expanded Opioid Controls:** New quantity limits across nearly all opioid products
- **Oncology Formulary Narrowed:** 17+ oral oncology drugs removed, including BRUKINSA, ZEJULA, LENVIMA, VITRAKVI, TAFINLAR/MEKINIST
- **Naloxone Access Expanded:** KLOXXADO and OPVEE added at Tier 1

**Critical Tier Changes:**
- **Cost Increases:** IBRANCE (Tier 2 â†’ Tier 4, added Step Therapy), CAPLYTA (Tier 2 â†’ Tier 4), triptans moved higher
- **Cost Decreases:** KISQALI (Tier 4 â†’ Tier 2), Rivastigmine (Tier 3 â†’ Tier 1), MS generics at Tier 1

**Specialty Seizure Medications Removed:** FINTEPLA (Dravet syndrome), vigabatrin, rufinamide, and felbamate no longer covered

ðŸ“„ **Detailed Analysis:** [pdf_direct.md](unitedhealthcare/pdf_direct.md) | [txt_extraction.md](unitedhealthcare/txt_extraction.md)

---

## Detailed Analysis Files

Each provider folder contains two analysis versions:

| Method | Description |
|--------|-------------|
| `pdf_direct.md` | PDFs sent directly to Claude for visual analysis of formulary tables |
| `txt_extraction.md` | Text extracted from PDFs, then analyzed for content comparison |

Both methods identify similar key changes but may emphasize different details based on document structure.

---

## Disclaimer

This analysis is generated by AI and should be verified against official formulary documents from each PBM. Coverage details may vary by specific plan design. Always consult official sources for member communications and clinical decisions.
